Cancer of the ovary

John Robert Lurain III, Michael J. Mckay, Colin A. Bull, Julio Collazos, John M. Embil, Stephen A. Cannistra

Research output: Contribution to journalLetter

1 Scopus citations

Abstract

To the Editor: Dr. Cannistra stated in his review article on cancer of the ovary (Nov. 18 issue)1 that “the regimen of cisplatin plus cyclophosphamide is just as effective as more complicated and toxic regimens, such as those containing altretamine or doxorubicin hydrochloride.” It appears that the author did not review the literature critically. For example, Hainsworth et al. (Cannistra's reference 42) reported a response rate of 96 percent for the combination of altretamine (hexamethylmelamine), cyclophosphamide, doxorubicin, and cisplatin (H-CAP)2. More important, the median survival for the entire group of patients was 45 months, and it was 72 months.

Original languageEnglish (US)
Pages (from-to)1012-1014
Number of pages3
JournalNew England Journal of Medicine
Volume330
Issue number14
DOIs
StatePublished - Apr 7 1994

    Fingerprint

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Lurain III, J. R., Mckay, M. J., Bull, C. A., Collazos, J., Embil, J. M., & Cannistra, S. A. (1994). Cancer of the ovary. New England Journal of Medicine, 330(14), 1012-1014. https://doi.org/10.1056/NEJM199404073301415